NEW YORK (GenomeWeb) – Veracyte said yesterday that it has expanded the early-access program (EAP) for its Envisia Genomic Classifier for differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs).
Veracyte launched the EAP in May to provide advance access to the test in anticipation of a nationwide launch in 2019.